home / stock / trov / trov short
Short Information | Cardiff Oncology (NASDAQ:TROV)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 3,608,017 |
Total Actual Volume | 17,332,860 |
Short Trends | |
---|---|
Cover Days | 18 |
Short Days | 2 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 180,401 |
Average Short Percentage | 29.82% |
Is there a TROV Short Squeeze or Breakout about to happen?
See the TROV Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-07-2020 | $1.19 | $1.19 | $1.19 | $1.16 | 166,427 | 50,896 | 30.58% |
05-06-2020 | $1.29 | $1.2 | $1.29 | $1.16 | 289,548 | 41,874 | 14.46% |
05-05-2020 | $1.22 | $1.2568 | $1.28 | $1.21 | 233,755 | 53,841 | 23.03% |
05-04-2020 | $1.17 | $1.215 | $1.25 | $1.12 | 275,611 | 72,010 | 26.13% |
05-01-2020 | $1.23 | $1.1501 | $1.24 | $1.13 | 264,157 | 41,211 | 15.6% |
04-30-2020 | $1.25 | $1.24 | $1.26 | $1.18 | 396,330 | 72,345 | 18.25% |
04-29-2020 | $1.12 | $1.1 | $1.124 | $1.01 | 355,913 | 542,472 | 152.42% |
04-28-2020 | $1.4277 | $1.11 | $1.67 | $1.09 | 12,713,837 | 2,138,387 | 16.82% |
04-27-2020 | $0.965 | $1.07 | $1.115 | $0.9625 | 676,980 | 122,258 | 18.06% |
04-24-2020 | $0.947 | $0.9653 | $0.97 | $0.92 | 151,968 | 32,785 | 21.57% |
04-23-2020 | $0.92 | $0.9499 | $0.965 | $0.9013 | 137,086 | 31,275 | 22.81% |
04-22-2020 | $0.88 | $0.93 | $0.9454 | $0.86 | 257,258 | 63,589 | 24.72% |
04-21-2020 | $0.93 | $0.9 | $0.93 | $0.85 | 156,941 | 33,081 | 21.08% |
04-20-2020 | $0.97 | $0.9 | $0.97 | $0.9 | 168,801 | 38,346 | 22.72% |
04-17-2020 | $0.9975 | $0.932 | $1.02 | $0.92 | 205,230 | 30,296 | 14.76% |
04-16-2020 | $0.9403 | $0.9605 | $1.0451 | $0.93 | 62,326 | 34,791 | 55.82% |
04-15-2020 | $1.03 | $0.9787 | $1.03 | $0.9 | 126,376 | 21,067 | 16.67% |
04-14-2020 | $1 | $1.0201 | $1.1 | $1 | 250,207 | 71,037 | 28.39% |
04-13-2020 | $0.95 | $0.96 | $1 | $0.9002 | 220,590 | 54,739 | 24.81% |
04-09-2020 | $0.79 | $0.91 | $0.9226 | $0.79 | 223,519 | 61,717 | 27.61% |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...